Bluejay Breakthrough Designation for Treatment for Chronic Hepatitis D

  Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced that its lead product candidate brelovitug (also known as BJT-778) has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD). There are currently no approved treatments for chronic hepatitis D in the United States and most countries around the world.

https://bluejaytx.com/bluejay-therapeutics-receives-u-s-fda-breakthrough-therapy-designation-for-brelovitug-bjt-778-for-the-treatment-of-chronic-hepatitis-delta/